[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

@aditharun_ Avatar @aditharun_ Adith Arun

Adith Arun posts on X about $fulc, $nvo, $arvn, $vtyx the most. They currently have XXXXX followers and XXX posts still getting attention that total XXX engagements in the last XX hours.

Engagements: XXX #

Engagements Line Chart

Mentions: XX #

Mentions Line Chart

Followers: XXXXX #

Followers Line Chart

CreatorRank: XXXXXXXXX #

CreatorRank Line Chart

Social Influence

Social category influence stocks cryptocurrencies currencies finance

Social topic influence $fulc #8, $nvo, $arvn #1, $vtyx, $mrsn, $dawn, at least, dawn, $prme, $kymr

Top accounts mentioned or mentioned by @3primeanalytica @plainyogurt21 @financebully @princetongb @avidresearch @houndcl @adamfeuerstein @zhaoweiasu @therealryc @naturemedicine @researchpulse1 @bingbingbom @biotech2k1 @adamcifu @varmaashwin97 @drsamuelbhume @anilmakam @geneinvesting @clarkitect80 @doctorveera

Top assets mentioned Novo-Nordisk (NVO) Arvinas, Inc (ARVN) Dawn Protocol (DAWN) Kymera Therapeutics, Inc. Common Stock (KYMR) Revolution Medicines, Inc. Common Stock (RVMD) GOSSIP-COIN (GOSS) Regeneron Pharmaceuticals Inc (REGN)

Top Social Posts

Top posts by engagements in the last XX hours

"Modifying neuroinflammation early in the disease process of Parkinson's disease and Alzheimer's disease to delay progression of disease $VTYX VTX3232 is going to try this out. What can we learn from $NVO though Semaglutide led to no significant difference in CDR-SB in patients with Alzheimer's disease. A XX% reduction in hs-CRP was noted in patients on semaglutide relative to placebo though. Inflammatory markers decreased considerably but no difference in outcomes. The interesting part is that $VTYX has a NLRP3i that drops hs-CRP by XX% in phase X studies and they are looking at Parkinson's"
X Link 2025-12-06T22:17Z 1231 followers, 2536 engagements

"$MRSN up XXX% $DAWN to acquire for 25/share with cash up to 30.25/share 🤯 tbh i didnt have this on my radar"
X Link 2025-11-13T14:30Z 1239 followers, 2050 engagements

"Forgot to mention - $PRME started accumulating when David Liu started making informative buys. Have done my own homework. Would recommend @zhaoweiasu. Also @medstudentinvst who gets technical with the gene editing tech. Plausible mechanism pathway from FDA is very exciting we will have to see what happens in the space"
X Link 2025-11-26T20:27Z 1261 followers, 1246 engagements

"@3primeAnalytica Everyone is chasing AATD"
X Link 2025-12-01T23:46Z 1261 followers, XXX engagements

"$FULC is the most promising sickle cell disease drug currently on the market. It also has the least data available. I will articulate my reasoning here: Gene editing approaches require chemo conditioning requiring in patient admission dealing with chemo toxicities (pretty bad) high up front cost (millions of dollars). There is an ongoing question as to whether the median patient wants this. Scalability remains a concern. $CRSP and $VRTX make Casgevy (FDA approved) -- apheresis busulfan conditioning then infuse ex-vivo edited hematopoietic stem cells (cas9 double stranded break of bcl11a"
X Link 2025-11-20T20:57Z 1261 followers, 16.3K engagements

"PROTAC vs RIPTAC vs MGD: PROTAC (proteolysis targeting chimeras): binder to protein of interest + linker + ligand recruits E3 ubiquitin ligase. Protein of interest is ubiquinated and degraded -- apoptosis from loss of function of protein of interest. $ARVN $KYMR $NRIX MGD (molecular glue degrader): monovalent low MW molecule that stabilizes protein-protein interaction between E3 ligase and target. Single interface. Can target proteins lacking traditionally ligand-able pockets. Makes for better oral drugs. $GLUE RIPTAC (regulated induced proximity targeting chimeras): binder to protein of"
X Link 2025-12-01T00:05Z 1262 followers, 1420 engagements

"$FULC up XX% after initial XX mg cohort data. Boom. More complete XX mg data on HbF induction at day XX to come in Q1 2026"
X Link 2025-12-08T16:34Z 1263 followers, 1284 engagements

"Two different therapies that drug the same pathway at different points are advancing to registrational trials in the same disease setting and line of therapy at roughly the same time. $RVMD RASolute XXX a Ph3 study of daraxonrasib (pan-KRASi) + chemo (GnP) compared to GnP alone in 1L mPDAC is exactly the stage and setting that $IMRX is positioning their MEKi. $IMRX is in phase X and will initiate phase X in 2026. $RVMD is a larger entity and can move faster and announced preliminary durability and data in 1H 2026. $IMRX is looking at MEKi + GnP in 1L mPDAC. They have some other combination"
X Link 2025-12-09T15:04Z 1264 followers, 2280 engagements

"- $FULC built a position around XX mg cohort and oral once daily PRC2i elevating HbF to a level that would meaningfully drop VOC burden for patients with SCD that was not controlled by HU or other drugs. Gene therapy is the future but that future will take time to be realized and made accessible and less resource-intensive. In the meantime oral daily pills for SCD offer a big advantage. Will have to wait and see what Q1 2026 XX mg d84 HbF absolute change is but so far trending in the right direction. Stock up XX% since news. One thing that had me waffling a little bit after writing this post"
X Link 2025-12-10T02:02Z 1263 followers, XXX engagements

"$arvn - protac company w X program waiting for partner and other protac/riptac companies surging $guts - many opinions from vulpes and others but small mc and interesting q1 readout pending $tenx - small but interesting player in ph space w goss tecx azn mrk and others $pmvp - what do u think about reactivator p53 molecules and management is what the question boils down to $xlo - warrants and interesting biology: masked tce"
X Link 2025-12-10T17:32Z 1264 followers, XXX engagements

"@zhaoweiasu @medstudentinvst Part of it is of course the macro environment and bull market of biotech ongoing. I can see the fulc reaction to interim data being flt to down a bit if the macro picture was tilted to a high interest rate bear market negative xbi sentiment"
X Link 2025-12-10T05:38Z 1264 followers, XXX engagements

"@bingbingbom $goss and $lxeo also interesting $regn if you like big companies $nvo if u want to speculate on glp1 game"
X Link 2025-12-10T17:35Z 1264 followers, XXX engagements